Updates are available Correction dated 2025-08-05
Click to view Correction: https://doi.org/10.1038/s41588-025-02320-0
-
Authors
Gundem, Gunes https://orcid.org/0000-0002-0070-9859
Levine, Max F.
Roberts, Stephen S.
Cheung, Irene Y.
Medina-MartÃnez, Juan S.
Feng, Yi
Arango-Ossa, Juan E. https://orcid.org/0000-0003-1109-6178
Chadoutaud, Loic
Rita, Mathieu
Asimomitis, Georgios https://orcid.org/0000-0002-9479-5451
Zhou, Joe
You, Daoqi https://orcid.org/0000-0003-4363-5893
Bouvier, Nancy
Spitzer, Barbara
Solit, David B. https://orcid.org/0000-0002-6614-802X
Dela Cruz, Filemon https://orcid.org/0000-0002-8356-5191
LaQuaglia, Michael P.
Kushner, Brian H.
Modak, Shakeel
Shukla, Neerav
Iacobuzio-Donahue, Christine A. https://orcid.org/0000-0002-4672-3023
Kung, Andrew L. https://orcid.org/0000-0002-9091-488X
Cheung, Nai-Kong V. https://orcid.org/0000-0001-6323-5171
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
-
Funding
Funding for this research was provided by:
Olayan Fund for Precision Pediatric Cancer Medicine
- License Information
-
More Information
Article History
Received: 6 January 2022
Accepted: 12 April 2023
First Online: 11 May 2023
Change Date: 5 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-025-02320-0
Competing interests
: G.G. is a consultant in Isabl Inc. E.P., A.L.K. and J.S.M-M. are founders, equity holders and hold fiduciary roles in Isabl Inc. N-K.V.C. reports receiving commercial research grants unrelated to this study, from Y-mAbs Therapeutics and Abpro Labs; holding ownership interest/equity in Y-mAbs Therapeutics and Abpro-Labs and owning stock options in Eureka Therapeutics. N-K.V.C. is the inventor and owner of issued patents, some licensed by MSKCC to Y-mAbs Therapeutics, Biotec Pharmacon and Abpro Labs. MSKCC also has financial interest in Y-mAbs Therapeutics. The remaining authors declare no competing interests.
